We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alnylam Pharmaceuticals Inc | NASDAQ:ALNY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.02 | 1.34% | 152.33 | 149.33 | 156.00 | 155.41 | 151.01 | 154.41 | 452,160 | 01:00:00 |
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 6, 2015
Alnylam Pharmaceuticals, Inc. |
(Exact Name of Registrant as Specified in Charter) |
Delaware |
001-36407 |
77-0602661 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
300 Third Street, Cambridge, MA |
02142 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (617) 551-8200
Not applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On August 6, 2015, Alnylam Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2015. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 Press Release dated August 6, 2015.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 6, 2015 |
ALNYLAM PHARMACEUTICALS, INC. |
||
|
|||
|
By: |
/s/ Michael P. Mason |
|
Michael P. Mason |
|||
Vice President, Finance and Treasurer |
EXHIBIT INDEX
Exhibit No. | Description | ||
99.1 |
Press Release dated August 6, 2015 |
Exhibit 99.1
Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities
– Advanced Pipeline of Seven Investigational Clinical Programs and Presented Positive Clinical Results for Three: Patisiran for Familial Amyloidotic Polyneuropathy (FAP), ALN-AT3 for Hemophilia, and ALN-CC5 for Complement-Mediated Diseases –
– In Addition to Upcoming Presentation of ALN-PCSsc Clinical Results, Announces New Plan to Present Initial Clinical Data for ALN-AS1 Porphyria Program at Medical Meeting in September and Provides Update on Revusiran Phase 2 Open-Label Extension Study –
– Maintained Strong Balance Sheet with $1.40 Billion in Cash and Remains On Track to End 2015 with Greater than $1.2 Billion in Cash –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 6, 2015--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2015, and highlighted recent progress in advancing its pipeline.
“The second quarter of 2015 and recent period were marked by tremendous progress in our efforts to bring innovative medicines to patients, as we execute on our ‘Alnylam 2020’ strategy. In our patisiran Phase 2 open-label extension – or ‘OLE’ – study, we believe to have generated increased evidence for a possible halting of neuropathy progression after the first 12 months of treatment, with study drug administration generally well tolerated out to 17 months. In our hemophilia program, we believe that recent results from our ongoing Phase 1 trial provide confirmatory evidence that ALN-AT3 has the potential to re-balance hemostasis in people with severe hemophilia through normalization of thrombin generation. We also reported initial positive data from our ongoing Phase 1/2 trial with ALN-CC5 – an investigational RNAi therapeutic for complement-mediated diseases – where we demonstrated what we believe to be promising preliminary clinical activity for single doses of study drug with potent and highly durable knockdown of serum C5 and inhibition of serum complement activity,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “We also completed enrollment in our ALN-PCSsc Phase 1 study with results to be presented later this month, and we started dosing in our patisiran APOLLO-OLE study and Phase 1 studies with ALN-AS1 and ALN-AAT. We now enter a very data-rich back half of the year, with important results being presented from six distinct clinical programs. We very much look forward to sharing these results in the weeks and months to come, as they highlight what we believe to be the significant potential for RNAi therapeutics as a new class of innovative medicines.”
Second Quarter 2015 and Recent Significant Corporate Highlights
Upcoming 3Q2015 Events
Upcoming RNAi Roundtables
Alnylam plans to continue hosting its series of online “RNAi Roundtables” in August and September, including events focused on the following RNAi therapeutics:
ALN-AAT for the treatment of AAT Deficiency-associated liver disease
Friday,
August 14, 2:00 – 3:00 p.m. ET
Patisiran and Revusiran for the treatment of Transthyretin
(TTR)-Mediated Amyloidosis
Thursday, August 20, 9:00 – 10:30
a.m. ET
The company announces today that it has scheduled additional RNAi Roundtables:
ALN-GO1 for the treatment of Primary Hyperoxaluria Type 1 (PH1)
Tuesday,
September 8, 9:00 – 10:00 a.m. ET
ALN-PCSsc for the treatment of Hypercholesterolemia
Wednesday,
September 16, 9:30 – 10:30 a.m. ET
ALN-AS1 for the treatment of Acute Hepatic Porphyrias
Thursday,
September 24, 11:00 am – 12:00 p.m. ET
Financials
“Alnylam continues to maintain a very strong balance sheet, with approximately $1.4 billion in cash as of the end of the second quarter of 2015,” said Michael Mason, Vice President, Finance & Treasurer. “As for financial guidance this year, we remain on track to end 2015 with greater than $1.2 billion in cash.”
Cash, Cash Equivalents and Total Marketable Securities
At June 30, 2015, Alnylam had cash, cash equivalents and total marketable securities of $1.40 billion, as compared to $881.9 million at December 31, 2014.
Non-GAAP Net Loss
The non-GAAP net loss for the second quarter of 2015 was $71.8 million, or $0.85 per share on both a basic and diluted basis as compared to a non-GAAP net loss of $48.0 million, or $0.63 per share on both a basic and diluted basis for the same period in the previous year. The non-GAAP net loss for the second quarter of 2014 excludes the $3.9 million reduction to in-process research and development expense for the purchase of the Sirna RNAi assets from Merck, described below, for which there is no corresponding expense for the second quarter of 2015.
GAAP Net Loss
The net loss according to accounting principles generally accepted in the U.S. (GAAP) for the second quarter of 2015 was $71.8 million, or $0.85 per share on both a basic and diluted basis (including $10.2 million, or $0.12 per share of non-cash stock-based compensation expense), as compared to a net loss of $44.1 million, or $0.58 per share on both a basic and diluted basis (including $7.7 million, or $0.10 per share of non-cash stock-based compensation expense), for the same period in the previous year.
Revenues
Revenues were $8.7 million for the second quarter of 2015, as compared to $7.3 million for the second quarter of 2014. Revenues for the second quarter of 2015 included $3.4 million from the company’s alliance with Takeda Pharmaceuticals Company Limited, $2.6 million from the company’s alliance with The Medicines Company, $2.6 million from the company’s alliance with Genzyme and $0.1 million from research reagent licenses and other sources. The increase in revenues in the second quarter of 2015 compared to the second quarter of the previous year was due primarily to services performed in connection with our performance obligations under agreements with The Medicines Company and Genzyme, partially offset by a decrease in revenue recognized under agreements with Monsanto and Takeda. The company expects net revenues from collaborators to decrease during the second half of 2015 on a comparative basis due primarily to the completion of our revenue amortization under the Takeda agreement in May 2015.
Research and Development Expenses
Research and development (R&D) expenses were $67.0 million in the second quarter of 2015 which included $6.1 million of non-cash stock-based compensation, as compared to $44.7 million in the second quarter of 2014, which included $2.6 million of non-cash stock-based compensation. The increase in R&D expenses in the second quarter of 2015 as compared to the second quarter of the prior year was due primarily to additional expenses related to the significant advancement of certain of our clinical and pre-clinical programs. In addition, compensation, non-cash stock-based compensation and related expenses increased during the second quarter of 2015 as compared to the second quarter of 2014 due primarily to a significant increase in headcount during the period as we continue to expand and advance our development pipeline. The company expects that research and development expenses will increase for the second half of 2015 as compared to the first half of 2015.
In-Process Research and Development Expense
In the second quarter of 2014, the company recorded a reduction of $3.9 million to in-process research and development expense in connection with the purchase of the Sirna RNAi assets from Merck. Upon the completion of certain technology transfer activities in the second quarter of 2014, the company issued an additional 378,007 shares of common stock to Merck. In the second quarter of 2014, the company re-measured the expense recorded in the first quarter of 2014 in connection with these shares using the price of the company’s common stock on the issuance date.
General and Administrative Expenses
General and administrative (G&A) expenses were $14.6 million in the second quarter of 2015, which included $4.0 million of non-cash stock-based compensation, as compared to $11.5 million in the second quarter of 2014, which included $5.1 million of non-cash stock-based compensation. The increase in G&A expenses in the second quarter of 2015 as compared to the second quarter of the prior year was due primarily to an increase in consulting and professional services related to an increase in general business activities. For the second half of 2015, the company expects that general and administrative expenses will increase slightly compared to the first half of 2015.
Conference Call Information
Management will provide an update on the company, discuss second quarter 2015 results, and discuss expectations for the future via conference call on Thursday, August 6, 2015 at 4:30 p.m. ET. To access the call, please dial 877-312-7507 (domestic) or 631-813-4828 (international) five minutes prior to the start time and refer to conference ID 95481472. A replay of the call will be available beginning at 7:30 p.m. ET on August 6, 2015. To access the replay, please dial 855-859-2056 (domestic) or 404-537-3406 (international), and refer to conference ID 95481472.
About RNAi
RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.
About GalNAc Conjugates and Enhanced Stabilization Chemistry (ESC) GalNAc Conjugates
GalNAc-siRNA conjugates are a proprietary Alnylam delivery platform and are designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor. Alnylam’s Enhanced Stabilization Chemistry (ESC) GalNAc-conjugate technology enables subcutaneous dosing with increased potency, durability, and a wide therapeutic index, and is being employed in several of Alnylam’s genetic medicine programs, including programs in clinical development.
About LNP Technology
Alnylam has licenses to Tekmira LNP intellectual property for use in RNAi therapeutic products using LNP technology.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs – including 4 in late stages of development – across its 3 STArs. The company’s demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information about Alnylam’s pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.
Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam’s future expectations, plans and prospects, including without limitation, Alnylam’s expectations regarding its “Alnylam 2020” guidance, Alnylam’s views with respect to the potential for RNAi therapeutics, including patisiran, revusiran, ALN-AT3, ALN-CC5, ALN-PCSsc, ALN-AS1, ALN-AAT, ALN-GO1 and its ESC-GalNAc-siRNA targeting TTR, its expectations with respect to the timing, execution, and success of its clinical and pre-clinical trials, the expected timing of regulatory filings, including its plan to file IND or IND equivalent applications, its expectations regarding reporting of data from its clinical and pre-clinical studies, including its studies for patisiran, revusiran, ALN-PCSsc, ALN-AS1, ALN-HBV, ALN-GO1 and its ESC-GalNAc-siRNA targeting TTR, its plans regarding commercialization of RNAi therapeutics, and Alnylam’s expected cash position as of December 31, 2015, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Alnylam’s ability to manage operating expenses, Alnylam’s ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Alnylam’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, obtaining regulatory approval for products, competition from others using technology similar to Alnylam’s and others developing products for similar uses, Alnylam’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Alnylam’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation to update any forward-looking statements.
Alnylam Pharmaceuticals, Inc. |
||||||||||||
Unaudited Condensed Consolidated Statements of Comprehensive Loss |
||||||||||||
(In thousands, except per share amounts) |
||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||
2015 | 2014 | 2015 | 2014 | |||||||||
Net revenues from collaborators | $ | 8,685 | $ | 7,295 | $ | 27,222 | $ | 15,570 | ||||
Operating expenses: | ||||||||||||
Research and development (1) |
67,007 | 44,672 | 125,042 | 88,430 | ||||||||
In-process research and development | — | (3,890) | — | 220,766 | ||||||||
General and administrative (1) | 14,622 | 11,518 | 27,346 | 20,443 | ||||||||
Total operating expenses | 81,629 | 52,300 | 152,388 | 329,639 | ||||||||
Loss from operations | (72,944) | (45,005) | (125,166) | (314,069) | ||||||||
Other income (expense): | ||||||||||||
Interest income | 1,619 | 693 | 2,633 | 1,026 | ||||||||
Other expense | (27) | (77) | (27) | (159) | ||||||||
Total other income | 1,592 | 616 | 2,606 | 867 | ||||||||
Loss before income taxes | (71,352) | (44,389) | (122,560) | (313,202) | ||||||||
(Provision for) Benefit from income taxes | (431) | 315 | — | 18,185 | ||||||||
Net loss | $ | (71,783) | $ | (44,074) | $ | (122,560) | $ | (295,017) | ||||
Net loss per common share - basic and diluted | $ | (0.85) | $ | (0.58) | $ | (1.47) | $ | (4.11) | ||||
Weighted average common shares used to compute basic and diluted net loss per common share | 84,353 | 75,835 | 83,219 | 71,833 | ||||||||
Comprehensive loss: | ||||||||||||
Net loss | $ | (71,783) | $ | (44,074) | $ | (122,560) | $ | (295,017) | ||||
Unrealized (loss) gain on marketable securities, net of tax | (33,623) | (3,047) | (30,001) | 2,266 | ||||||||
Comprehensive loss | $ | (105,406) | $ | (47,121) | $ | (152,561) | $ | (292,751) | ||||
(1) Non-cash stock-based compensation expenses included in operating expenses are as follows: | ||||||||||||
Research and development | $ | 6,149 | $ | 2,557 | $ | 11,495 | $ | 6,238 | ||||
General and administrative | 4,030 | 5,123 | 6,920 | 7,033 | ||||||||
Alnylam Pharmaceuticals, Inc. |
||||||||||||
Unaudited GAAP to Non-GAAP Reconciliation: Net Loss and Net Loss Per Share |
||||||||||||
(In thousands, except per share amounts) |
||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||
2015 | 2014 | 2015 | 2014 | |||||||||
GAAP net loss | $ | (71,783) | $ | (44,074) | $ | (122,560) | $ | (295,017) | ||||
Adjustment: | ||||||||||||
In-process research and development | — | (3,890) | — | 220,766 | ||||||||
Non-GAAP net loss | $ | (71,783) | $ | (47,964) | $ | (122,560) | $ | (74,251) | ||||
GAAP net loss per common share - basic and diluted | $ | (0.85) | $ | (0.58) | $ | (1.47) | $ | (4.11) | ||||
Adjustment (as detailed above) | — | (0.05) | — | 3.08 | ||||||||
Non-GAAP net loss per common share - basic and diluted | $ | (0.85) | $ | (0.63) | $ | (1.47) | $ | (1.03) | ||||
Use of Non-GAAP Financial Measures
The company supplements its condensed consolidated financial statements presented on a GAAP basis by providing additional measures that are considered “non-GAAP” financial measures under applicable SEC rules. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles in the United States (GAAP) and should not be viewed in isolation or as a substitute for GAAP net loss and basic and diluted net loss per common share.
The company evaluates items on an individual basis, and considers both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to the company’s ongoing business operations, and (iii) whether or not the company expects it to occur as part of its normal business on a regular basis. In the second quarter of 2014 and first half of 2014, the company’s Non-GAAP net loss and Non-GAAP loss per common share – basic and diluted financial measures excludes the in-process research and development reduction to expense of $3.9 million and expense of $220.8 million, respectively, related to the purchase of the Sirna RNAi assets from Merck. The company believes that the exclusion of this item provides management and investors with supplemental measures of performance that better reflect the underlying economics of the company’s business. In addition, the company believes the exclusion of this item is important in comparing current results with prior period results and understanding projected operating performance. Management uses these non-GAAP financial measures to establish budgets and operational goals and to manage the company’s business.
ALNYLAM PHARMACEUTICALS, INC. |
||||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||
(In thousands, except share amounts) |
||||||
June 30, | December 31, | |||||
2015 | 2014 | |||||
Cash, cash equivalents and total marketable securities | $ | 1,396,800 | $ | 881,929 | ||
Billed and unbilled collaboration receivables | 9,403 | 39,937 | ||||
Prepaid expenses and other current assets | 15,117 | 9,739 | ||||
Deferred tax assets | 19,654 | 31,667 | ||||
Property and equipment, net | 25,169 | 21,740 | ||||
Investment in equity securities of Regulus Therapeutics Inc. | 64,628 | 94,583 | ||||
Total assets | $ | 1,530,771 | $ | 1,079,595 | ||
Accounts payable and accrued expenses | $ | 33,473 | $ | 38,791 | ||
Deferred tax liabilities | 19,654 | 31,667 | ||||
Total deferred revenue | 62,716 | 66,854 | ||||
Total deferred rent | 6,324 | 6,016 | ||||
Total stockholders’ equity (84.5 million and 77.2 million common shares issued and outstanding and at June 30, 2015 and December 31, 2014, respectively) | 1,408,604 | 936,267 | ||||
Total liabilities and stockholders' equity | $ | 1,530,771 | $ | 1,079,595 | ||
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alnylam’s Annual Report on Form 10-K which includes the audited financial statements for the year ended December 31, 2014.
CONTACT:
Alnylam Pharmaceuticals, Inc.
Michael Mason,
617-551-8327
Vice President, Finance and Treasurer
or
Joshua
Brodsky, 617-551-8276
Senior Manager, Investor Relations and
Corporate
Communications
1 Year Alnylam Pharmaceuticals Chart |
1 Month Alnylam Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions